AmerisourceBergen Reports $0.87 in Diluted EPS from Continuing Operations, and Revenue of $20.5 Billion for the March 2013

  AmerisourceBergen Reports $0.87 in Diluted EPS from Continuing Operations,
  and Revenue of $20.5 Billion for the March 2013 Quarter

Business Wire

VALLEY FORGE, Pa. -- April 25, 2013

AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal
year 2013 second quarter, ended March 31, 2013, diluted earnings per share
from continuing operations were $0.87, a 4 percent increase. Revenue in the
quarter was $20.5 billion, up 4 percent. The Company also reaffirmed its
expectations for fiscal year 2013 adjusted diluted earnings per share from
continuing operations in the range of $3.04 to $3.14, though likely in the
lower half of the range. All the results are presented in accordance with U.S.
generally accepted accounting principles (GAAP).

Fiscal Second Quarter Highlights

  *Revenue of $20.5 billion, up 4.1 percent.
  *Diluted earnings per share from continuing operations of $0.87, a 3.6
    percent increase.
  *Gross profit of $717.0 million, up 5.5 percent.
  *Cash flow from operations of $985.4 million.

Fiscal First Six Months Highlights

  *Revenue of $41.6 billion, up 4.8 percent.
  *Diluted earnings per share from continuing operations of $1.61, up 11.0
    percent.
  *Gross profit of $1.4 billion, up 10.0 percent.
  *Cash flow from operations of $743.7 million.
  *Share repurchases of $284.7 million.

“We are off to a solid start in the first half of our fiscal year,” said
Steven H. Collis, AmerisourceBergen President and Chief Executive Officer. “In
addition, during the quarter, we took several steps to enhance the long-term
growth prospects for AmerisourceBergen, including the announcement of
agreements of sale for AndersonBrecon and our Canadian distribution business,
and most significantly, a new strategic long-term relationship with Walgreen
Co. and Alliance Boots GmbH. We are very excited about the opportunities that
lie ahead for our core businesses, and the prospects for new business
development we see on a global basis. Over the next few quarters, our drug
wholesale business will significantly expand as we start servicing all the
pharmaceutical products for the largest U.S. drug store chain. Moreover, our
global partnership provides an unprecedented platform to innovate by
leveraging on each company’s respective strengths to unlock value in the
pharmaceutical supply chain to the benefit of all our stakeholders.”

Summary of Quarterly Results

  *Revenue: Revenue was $20.5 billion in the second quarter of fiscal 2013, a
    4.1 percent increase over the same quarter in the previous fiscal year,
    driven by a 3.9 percent increase in AmerisourceBergen Drug Corporation
    (ABDC) revenue, a 3.9 percent increase in AmerisourceBergen Specialty
    Group (ABSG) revenue, and a 46.9 percent increase in our manufacturer
    services businesses, reported in Other.
  *Gross Profit: Gross profit in the fiscal 2013 second quarter was $717.0
    million, a 5.5 percent increase over the year-ago same period driven
    primarily by contributions from the recent addition of World Courier,
    which was offset in part by a decline in gross profit in ABDC and ABSG.
    Gross profit as a percentage of revenue was 3.49 percent, a 4 basis point
    improvement over the same period in the previous year.
  *Operating Expenses: For the second quarter of fiscal 2013, operating
    expenses were $366.9 million compared with $302.7 million in the prior
    fiscal year’s second quarter, a 21.2 percent increase. The increase in
    operating expenses was primarily due to the operating expenses of World
    Courier, which were not in the prior year quarter, and increased
    depreciation and amortization costs. Compared to the prior year, operating
    expenses as a percentage of revenue in the fiscal second quarter of 2013
    were up 25 basis points to 1.79 percent.
  *Operating Income: In the fiscal 2013 second quarter, operating income
    decreased 7.1 percent to $350.1 million, due to the increase in operating
    expenses which was offset in part by the increase in gross profit.
    Operating income as a percentage of revenue decreased 20 basis points to
    1.71 percent in the period compared with the previous year’s second
    quarter.
  *Tax Rate: The effective tax rate for the second quarter of fiscal 2013 was
    38.3 percent, compared to 38.1 percent in the previous fiscal year’s
    second quarter. Going forward, we expect our annualized effective tax rate
    to be approximately 38.2 percent.
  *Earnings Per Share: Diluted earnings per share from continuing operations
    were up 3.6 percent to $0.87 in the second quarter of fiscal 2013 compared
    to $0.84 in the previous fiscal year’s second quarter. Diluted earnings
    per share growth was driven by the 10.6 percent reduction in diluted
    average shares outstanding.
  *Shares Outstanding: Diluted average shares outstanding for the second
    quarter of fiscal year 2013 were 234.6 million, down 27.8 million shares
    from the previous fiscal year’s second quarter due primarily to share
    repurchases, net of option exercises over the last twelve months.

Segment Discussion

The Pharmaceutical Distribution segment includes both AmerisourceBergen Drug
Corporation and AmerisourceBergen Specialty Group. Other includes
AmerisourceBergen Consulting Services (ABCS) and World Courier. The results of
operations of AndersonBrecon and AmerisourceBergen Canada Corporation as well
as the estimated loss on sale of AmerisourceBergen Canada Corporation, are
reported as discontinued operations.

Pharmaceutical Distribution Segment

In the second fiscal quarter of 2013, Pharmaceutical Distribution revenues
were $20.1 billion, an increase of 3 percent compared to the same quarter in
the prior year. ABDC revenues increased 4 percent, due primarily to an
increase in sales volume resulting from the October 2012 implementation of the
large PBM customer contract, offset in part by the loss of a food and drug
retail group purchasing organization customer. ABSG revenues increased 4
percent, which was driven by strong performance in our third party logistics,
blood products, vaccine, and physician office distribution businesses.
Intrasegment revenues between ABDC and ABSG have been eliminated in the
presentation of total Pharmaceutical Distribution revenue. Total intrasegment
revenues were $764.3 million and $660.1 million in the quarters ended March
31, 2013 and 2012, respectively.

Operating income of $328.6 million in the March quarter of fiscal 2013
decreased 9 percent compared to the same period in the previous year driven by
a 23 basis point decline in operating margin due to a shift in customer mix
towards lower margin business in both ABDC and ABSG, disappointing performance
in our oncology business, and fewer new generic launches to offset those
impacts.

Other

Revenues included in Other were $435.4 million in the second quarter of fiscal
2013, including significant contributions from World Courier, which was not
included in the same quarter in the previous year. Gross profit and operating
expenses also increased significantly compared to the prior year quarter due
to the inclusion of operating results from World Courier. Operating income
increased 5 percent to $25.0 million in the second quarter of fiscal 2013, due
to contributions from World Courier offset by a decline in operating income in
ABCS.

Fiscal Year 2013 Expectations

“Looking ahead, the Company expects adjusted diluted earnings per share from
continuing operations in fiscal year 2013 to be in the lower half of the range
of $3.04 to $3.14, excluding certain expenses related to our new strategic
long-term relationship with Walgreens and Alliance Boots, including the
warrants issued, and the expected LIFO charge from onboarding of additional
branded inventory.” said Steven H. Collis, AmerisourceBergen President and
Chief Executive Officer. “Excluding the two items mentioned above, we now
expect revenue growth in the 11 percent to 13 percent range; operating income
decline in the 3 percent to 5 percent range; an operating margin decline in
the range of 24 to 29 basis points; and free cash flow in the range of $100
million to $200 million, which includes capital expenditures of at least $220
million. Subject to market conditions, we continue to expect to spend
approximately $400 million to repurchase our common shares in fiscal year
2013.”

Adjusted Fiscal Year 2012 Financial Results

As a result of the pending sale of AmerisourceBergen Canada Corporation and
the classifying of its operating results as discontinued operations, the
Company will retroactively adjust its financial results for fiscal year 2012.
Total consolidated revenues for AmerisourceBergen in fiscal 2012 will be
adjusted to $78.1 billion, consolidated operating income will be adjusted to
$1.3 billion, and GAAP diluted earnings per share from continuing operations
will be adjusted to $2.96. We expect to provide further details, including
adjusted quarterly consolidated results via a Form 8-K filing shortly after we
file our Form 10-Q for the quarter ended March 31, 2013.

Conference Call

The Company will host a conference call to discuss its results at 11:00 a.m.
Eastern Standard Time on April 25, 2013. Participating in the conference call
will be: Steven H. Collis, President and Chief Executive Officer; and Tim G.
Guttman, Senior Vice President and Chief Financial Officer.

To access the live conference call via telephone:

Dial in: The dial-in number for the live call will be 612-332-0107. No access
code is needed.

To access the live webcast:

Go to the Investor Relations page at http://www.amerisourcebergen.com.

A replay of the telephone call and webcast will be available from 2:30 p.m.
April 25, 2013 until 11:59 p.m. May 2, 2013. The Webcast replay will be
available for 30 days.

To access the telephone replay from within the US, dial 800-475-6701. From
outside the US, dial 320-365-3844. The access code for the replay is 288282.

To access the archived webcast:

Go to the Quarterly Webcasts section on the Investor Relations page at
http://www.amerisourcebergen.com.

Upcoming Conferences

AmerisourceBergen management will be attending the Bank of America Healthcare
Conference in Las Vegas, NV on May 14, 2013, the UBS Healthcare conference in
New York, NY on May 20, 2013, and the Goldman Sachs Healthcare Conference in
Rancho Palos Verde, CA on June 12, 2013.

About AmerisourceBergen

AmerisourceBergen is one of the world's largest pharmaceutical services
companies serving the United States, Canada and selected global markets.
Servicing both healthcare providers and pharmaceutical manufacturers in the
pharmaceutical supply channel, the Company provides drug distribution and
related services designed to reduce costs and improve patient outcomes.
AmerisourceBergen's service solutions range from niche premium logistics and
pharmaceutical packaging to reimbursement and pharmaceutical consulting
services. With over $80 billion in annualized revenue, AmerisourceBergen is
headquartered in Valley Forge, PA, and employs approximately 13,000 people.
AmerisourceBergen is ranked #29 on the Fortune 500 list. For more information,
go to www.amerisourcebergen.com.

Cautionary Note Regarding Forward-Looking Statements

Certain of the statements contained in this press release are "forward-looking
statements" within the meaning of Section 27A of the Securities Act of 1933
and Section 21E of the Securities Exchange Act of 1934. Words such as
“expect,” “likely,” “outlook,” “forecast,” “would,” “could,” “should,” “can,”
“will,” “project,” “intend,” “plan,” “continue,” “sustain,” “synergy”, “on
track,” “believe,” “seek,” “estimate,” “anticipate,” “may,” ”possible,”
“assume,” variations of such words and similar expressions are intended to
identify such forward-looking statements. These statements are based on
management's current expectations and are subject to uncertainty and change in
circumstances. These statements are not guarantees of future performance, are
based on assumptions that could prove incorrect or could cause actual results
to vary materially from those indicated. Among the factors that could cause
actual results to differ materially from those projected, anticipated or
implied are the following: changes in pharmaceutical market growth rates; the
loss of one or more key customer or supplier relationships; changes in
customer mix; customer delinquencies, defaults or insolvencies; supplier
defaults or insolvencies; changes in pharmaceutical manufacturers' pricing and
distribution policies or practices; adverse resolution of any contract or
other dispute with customers or suppliers; federal and state government
enforcement initiatives to detect and prevent suspicious orders of controlled
substances and the diversion of controlled substances; qui tam litigation for
alleged violations of fraud and abuse laws and regulations and/or any other
laws and regulations governing the marketing, sale, purchase, and/or
dispensing of pharmaceutical products or services and any related litigation,
including shareholder derivative lawsuits; changes in federal and state
legislation or regulatory action affecting pharmaceutical product pricing or
reimbursement policies, including under Medicaid and Medicare; changes in
regulatory or clinical medical guidelines and/or labeling for the
pharmaceutical products we distribute, including certain anemia products;
price inflation in branded pharmaceuticals and price deflation in generics;
greater or less than anticipated benefit from launches of the generic versions
of previously patented pharmaceutical products; significant breakdown or
interruption of our information technology systems; our inability to realize
the anticipated benefits of the implementation of an enterprise resource
planning (ERP) system; interest rate and foreign currency exchange rate
fluctuations; risks associated with international business operations,
including non-compliance with the U.S. Foreign Corrupt Practices Act,
anti-bribery laws and economic sanctions and import laws and regulations;
economic, business, competitive and/or regulatory developments outside of the
United States; risks associated with the strategic, long-term relationship
among Walgreen Co., Alliance Boots GmbH, and AmerisourceBergen, including the
failure to obtain the required U.S. and foreign antitrust regulatory approvals
for the equity investments by Walgreens and Alliance Boots in
AmerisourceBergen, the occurrence of any event, change or other circumstance
that could give rise to the termination, cross-termination or modification of
any of the transaction documents among the parties (including, among others,
the distribution agreement or the generics agreement), an impact on our
earnings per share resulting from the issuance of the warrants, an inability
to realize anticipated benefits (including benefits resulting from
participation in the Walgreens Boots Alliance Development GmbH joint venture),
the disruption of AmerisourceBergen’s cash flow and ability to return value to
its stockholders in accordance with its past practices, disruption of or
changes in vendor, payer and customer relationships and terms, and the
reduction of AmerisourceBergen’s operational, strategic or financial
flexibility; the acquisition of businesses that do not perform as we expect or
that are difficult for us to integrate or control; our inability to
successfully complete any other transaction that we may wish to pursue from
time to time; changes in tax laws or legislative initiatives that could
adversely affect our tax positions and/or our tax liabilities or adverse
resolution of challenges to our tax positions; increased costs of maintaining,
or reductions in our ability to maintain, adequate liquidity and financing
sources; volatility and deterioration of the capital and credit markets; and
other economic, business, competitive, legal, tax, regulatory and/or
operational factors affecting our business generally. Certain additional
factors that management believes could cause actual outcomes and results to
differ materially from those described in forward-looking statements are set
forth (i) in Item 1A (Risk Factors) in the Company's Annual Report on Form
10-K for the fiscal year ended September 30, 2012 and elsewhere in that report
and (ii) in other reports filed by the Company pursuant to the Securities
Exchange Act of 1934. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date they are made.
Except to the extent required by law, AmerisourceBergen does not undertake,
and expressly disclaims, any duty or obligation to publicly update any
forward-looking statement after the date of this report, whether as a result
of new information, future events, changes in assumptions or otherwise.

               
AMERISOURCEBERGEN CORPORATION
FINANCIAL SUMMARY
(In thousands, except per share data)
(unaudited)
                                                                  
                                                                       
                 Three                      Three
                 Months Ended               Months Ended
                 March 31,       % of       March 31,       % of       %
                 2013            Revenue    2012            Revenue    Change
                                                                       
Revenue          $20,523,668     100.00 %   $19,708,371     100.00 %   4.1   %
                                                                       
Cost of goods    19,806,679                19,028,630                4.1   %
sold
                                                                       
Gross profit     716,989         3.49   %   679,741         3.45   %   5.5   %
(1)
                                                                       
Operating
expenses:
Distribution,
selling and      323,536         1.58   %   262,421         1.33   %   23.3  %
administrative
Depreciation
and              39,868          0.19   %   31,233          0.16   %   27.6  %
amortization
Warrants (2)     3,761           0.02   %   -               -      %
Employee
severance,       (299        )   -      %   9,027          0.05   %
litigation and
other, net (3)
Total
operating        366,866         1.79   %   302,681         1.54   %   21.2  %
expenses
                                                                       
Operating        350,123         1.71   %   377,060         1.91   %   -7.1  %
income
                                                                       
Other loss       749             -      %   (131        )   -      %
(income)
                                                                       
Interest         18,510         0.09   %   23,375         0.12   %   -20.8 %
expense, net
                                                                       
Income from
continuing
operations       330,864         1.61   %   353,816         1.80   %   -6.5  %
before income
taxes
                                                                       
Income taxes     126,721        0.62   %   134,673        0.68   %   -5.9  %
                                                                       
Income from
continuing       204,143         0.99   %   219,143         1.11   %   -6.8  %
operations
                                                                       
Loss from
discontinued
operations,      (158,509    )              (7,038      )
net of income
taxes
                                                                       
Net income       $45,634        0.22   %   $212,105       1.08   %
                                                                       
                                                                       
Basic earnings
per share:
Continuing       $0.89                      $0.85                      4.7   %
operations
Discontinued     (0.69       )              (0.03       )
operations
Total            $0.20                     $0.82       
                                                                       
Diluted
earnings per
share:
Continuing       $0.87                      $0.84                      3.6   %
operations
Discontinued     (0.68       )              (0.03       )
operations
Total            $0.19                     $0.81       
                                                                       
Weighted
average common
shares
outstanding:
Basic            230,422                    258,162
Diluted (4)      234,587                    262,363                    -10.6 %
                                                                       

(1)  Includes a $3.5 million gain from antitrust litigation settlements in
      the three months ended March 31, 2013.
      Expense related to common stock warrants issued to Walgreens and
(2)   Alliance Boots in connection with the March 19, 2013 announced
      agreements and arrangements.
      Includes the net reversal of $(4.5) million of employee severance and
      other restructuring costs and $4.2 million of deal-related transaction
(3)   costs in the three months ended March 31, 2013. Includes $6.1 million of
      employee severance costs and $2.9 million of deal-related transaction
      costs in the three months ended March 31, 2012.
(4)   Includes the dilutive effect of stock options, restricted stock, and
      restricted stock units.
      


AMERISOURCEBERGEN CORPORATION
FINANCIAL SUMMARY
(In thousands, except per share data)
(unaudited)
                                                                 
                                                                       
                 Six                        Six
                 Months Ended               Months Ended
                 March 31,       % of       March 31,       % of       %
                 2013            Revenue    2012            Revenue    Change
                                                                       
Revenue          $41,583,479     100.00 %   $39,689,556     100.00 %   4.8   %
                                                                       
Cost of goods    40,205,662                38,436,553                4.6   %
sold
                                                                       
Gross profit     1,377,817       3.31   %   1,253,003       3.16   %   10.0  %
(1)
                                                                       
Operating
expenses:
Distribution,
selling and      644,236         1.55   %   519,606         1.31   %   24.0  %
administrative
Depreciation
and              78,552          0.19   %   60,348          0.15   %   30.2  %
amortization
Warrants (2)     3,761           0.01   %   -               -      %
Employee
severance,       1,705          -      %   12,586         0.03   %
litigation and
other (3)
Total
operating        728,254         1.75   %   592,540         1.49   %   22.9  %
expenses
                                                                       
Operating        649,563         1.56   %   660,463         1.66   %   -1.7  %
income
                                                                       
Other loss       726             -      %   (132        )   -      %
(income)
                                                                       
Interest         37,035         0.09   %   45,661         0.12   %   -18.9 %
expense, net
                                                                       
Income from
continuing
operations       611,802         1.47   %   614,934         1.55   %   -0.5  %
before income
taxes
                                                                       
Income taxes     233,038        0.56   %   234,199        0.59   %   -     %
                                                                       
Income from
continuing       378,764         0.91   %   380,735         0.96   %   -0.5  %
operations
                                                                       
Loss from
discontinued
operations,      (164,519    )              (6,514      )
net of income
taxes
                                                                       
Net income       $214,245       0.52   %   $374,221       0.94   %
                                                                       
                                                                       
Basic earnings
per share:
Continuing       $1.64                      $1.47                      11.6  %
operations
Discontinued     (0.71       )              (0.03       )
operations
Rounding         -                         0.01        
Total            $0.93                     $1.45       
                                                                       
Diluted
earnings per
share:
Continuing       $1.61                      $1.45                      11.0  %
operations
Discontinued     (0.70       )              (0.02       )
operations
Rounding         -                         (0.01       )
Total            $0.91                     $1.42       
                                                                       
Weighted
average common
shares
outstanding:
Basic            231,409                    258,316
Diluted (4)      235,307                    262,729                    -10.4 %
                                                                       

(1)  Includes a $15.8 million gain from antitrust litigation settlements in
      the six months ended March 31, 2013.
      Expense related to common stock warrants issued to Walgreens and
(2)   Alliance Boots in connection with the March 19, 2013 announced
      agreements and arrangements.
      Includes $4.7 million of deal-related transaction costs and the net
      reversal of $(3.0) million of employee severance and other restructuring
(3)   costs in the six months ended March 31, 2013. Includes $6.1 million of
      employee severance costs and $6.5 million of deal-related transaction
      costs in the six months ended March 31, 2012.
(4)   Includes the dilutive effect of stock options, restricted stock, and
      restricted stock units.
      


AMERISOURCEBERGEN CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
(unaudited)


ASSETS                                                  
                                             March 31,     September 30,
                                             2013          2012
Current assets:
Cash and cash equivalents                    $1,347,297    $1,066,608
Accounts receivable, net                     4,180,449     3,784,620
Merchandise inventories                      5,662,556     5,472,010
Prepaid expenses and other                   72,707        72,374
Assets held for sale                         461,775       662,851
Total current assets                         11,724,784    11,058,463
                                                           
Property and equipment, net                  762,237       743,685
Other long-term assets                       3,624,410     3,640,108
                                                           
Total assets                                 $16,111,431   $15,442,256
                                                           
                                                           
LIABILITIES AND STOCKHOLDERS' EQUITY
                                                           
Current liabilities:
Accounts payable                             $10,362,227   $9,492,589
Other current liabilities                    1,468,186     1,533,290
Liabilities held for sale                    212,238       239,707
Total current liabilities                    12,042,651    11,265,586
                                                           
Long-term debt                               1,396,272     1,395,931
                                                           
Other long-term liabilities                  326,228       325,897
                                                           
Stockholders' equity                         2,346,280     2,454,842
                                                           
Total liabilities and stockholders' equity   $16,111,431   $15,442,256
                                                           


AMERISOURCEBERGEN CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
                                                               
                                                   Six            Six
                                                   Months Ended   Months Ended
                                                   March 31,      March 31,
                                                  2013           2012
                                                                  
Operating Activities:
Net income                                         $214,245       $374,221
Loss from discontinued operations                  164,519       6,514      
Income from continuing operations                  378,764        380,735
Adjustments to reconcile income from continuing
operations to net cash provided by operating       141,401        119,324
activities
Changes in operating assets and liabilities        178,059       242,318    
Net cash provided by operating activities -        698,224        742,377
continuing operations
Net cash provided by (used in) operating           45,431        (74,253    )
activities - discontinued operations
Net cash provided by operating activities          743,655       668,124    
                                                                  
Investing Activities:
Capital expenditures                               (88,377    )   (63,481    )
Cost of acquired companies, net of cash acquired   -              (257,658   )
Other                                              81            -          
Net cash used in investing activities -            (88,296    )   (321,139   )
continuing operations
Net cash used in investing activities -            (9,643     )   (24,717    )
discontinued operations
Net cash used in investing activities              (97,939    )   (345,856   )
                                                                  
Financing Activities:
Net borrowings                                     -              444,290
Purchases of common stock                          (284,691   )   (328,504   )
Exercises of stock options                         65,850         71,084
Cash dividends on common stock                     (98,203    )   (67,429    )
Debt issuance costs and other                      (6,086     )   (10,523    )
Net cash (used in) provided by financing           (323,130   )   108,918
activities - continuing operations
Net cash (used in) provided by financing           (41,897    )   69,918     
activities - discontinued operations
Net cash (used in) provided by financing           (365,027   )   178,836    
activities
                                                                  
Increase in cash and cash equivalents              280,689        501,104
                                                                  
Cash and cash equivalents at beginning of period   1,066,608     1,825,990  
                                                                  
Cash and cash equivalents at end of period         $1,347,297    $2,327,094 
                                                                  


AMERISOURCEBERGEN CORPORATION
SUMMARY SEGMENT INFORMATION
(dollars in thousands)
(unaudited)
                                                                  
                                                                      
                                      Three Months Ended March 31,
Revenue                               2013           2012           % Change
                                                                      
Pharmaceutical Distribution           $20,133,717     $19,454,919     3     %
Other (1)                             435,384         296,401         47    %
Intersegment eliminations             (45,433     )   (42,949     )   6     %
                                                                      
Revenue                               $20,523,668    $19,708,371    4     %
                                                                      
                                                                      
                                                                      
                                                                      
                                      Three Months Ended March 31,
Operating Income                      2013           2012           % Change
                                                                      
Pharmaceutical Distribution           $328,635        $362,363        -9    %
Other (1)                             24,950          23,724          5     %
Warrants                              (3,761      )   -               N/M
Employee severance, litigation and    299            (9,027      )   N/M
other
                                                                      
Operating income                      $350,123       $377,060       -7    %
                                                                      
                                                                      
                                                                      
                                                                      
Percentages of revenue:
                                                                      
Pharmaceutical Distribution
Gross profit                          2.98        %   3.24        %
Operating expenses                    1.35        %   1.38        %
Operating income                      1.63        %   1.86        %
                                                                      
Other (1)
Gross profit                          26.87       %   16.77       %
Operating expenses                    21.14       %   8.77        %
Operating income                      5.73        %   8.00        %
                                                                      
AmerisourceBergen Corporation
Gross profit                          3.49        %   3.45        %
Operating expenses                    1.79        %   1.54        %
Operating income                      1.71        %   1.91        %
                                                                      

(1) Other for the three months ended March 31, 2013 is comprised of the
AmerisourceBergen Consulting Services ("ABCS") operating segment and the World
Courier Group, Inc. operating segment. Other for the three months ended March
31, 2012 is comprised solely of the ABCS operating segment.



AMERISOURCEBERGEN CORPORATION
SUMMARY SEGMENT INFORMATION
(dollars in thousands)
(unaudited)
                                                                  
                                                                      
                                      Six Months Ended March 31,
Revenue                               2013           2012           % Change
                                                                      
Pharmaceutical Distribution           $40,809,925     $39,258,232     4     %
Other (1)                             863,274         505,726         71    %
Intersegment eliminations             (89,720     )   (74,402     )   21    %
                                                                      
Revenue                               $41,583,479    $39,689,556    5     %
                                                                      
                                                                      
                                                                      
                                                                      
                                      Six Months Ended March 31,
Operating Income                      2013           2012           % Change
                                                                      
Pharmaceutical Distribution           $609,520        $639,719        -5    %
Other (1)                             45,509          33,330          37    %
Warrants                              (3,761      )   -               N/M
Employee severance, litigation and    (1,705      )   (12,586     )   N/M
other
                                                                      
Operating income                      $649,563       $660,463       -2    %
                                                                      
                                                                      
                                                                      
                                                                      
Percentages of revenue:
                                                                      
Pharmaceutical Distribution
Gross profit                          2.81        %   2.99        %
Operating expenses                    1.32        %   1.36        %
Operating income                      1.49        %   1.63        %
                                                                      
Other (1)
Gross profit                          26.71       %   16.01       %
Operating expenses                    21.44       %   9.42        %
Operating income                      5.27        %   6.59        %
                                                                      
AmerisourceBergen Corporation
Gross profit                          3.31        %   3.16        %
Operating expenses                    1.75        %   1.49        %
Operating income                      1.56        %   1.66        %
                                                                      

(1) Other for the six months ended March 31, 2013 is comprised of the
AmerisourceBergen Consulting Services ("ABCS") operating segment and the World
Courier Group, Inc. operating segment. Other for the six months ended March
31, 2012 is comprised solely of the ABCS operating segment.


Contact:

AmerisourceBergen Corporation
Barbara Brungess, 610-727-7199
bbrungess@amerisourcebergen.com
 
Press spacebar to pause and continue. Press esc to stop.